Mazdutide
Also known as GLP-1 / glucagon dual agonist
GLP-1 and glucagon receptor dual agonist
An oxyntomodulin-based dual agonist studied for weight reduction with an added energy-expenditure component.
How it works
Pairs GLP-1 appetite suppression with glucagon receptor signaling, which increases resting energy expenditure and hepatic fat mobilization.
What research has shown
Phase 2 and 3 data report weight reductions of roughly 10 to 15% over 24 to 48 weeks alongside reductions in liver fat.
Reported ranges in the literature
Low end
1.5 mg weekly
Optimal
4 mg weekly
High end
6 to 9 mg weekly in reported trials
Frequency reported in the literature: Once weekly
Protocol duration and pairing
Typical study duration
24 to 48 week phase 2 and 3 protocols.
Best paired with
Glucagon receptor activity overlaps with thermogenic compounds, so stacking is not well characterized.
Research use only
All content on this page is general reference information for laboratory research contexts. It is not medical advice, is not intended to direct human use, and does not replace guidance from a licensed healthcare professional. Not for human consumption. Must be 18+.